@Shifted I think this is the biggest difference in such a study that doesn't compare dosing regimen of RUO vs Lilly reta.

RUO dosing isn't as "standardized" and has people starting lower (as low as 0.5mg) and not titrating as fast as Lilly. Many people don't cross 4mg.

Lilly protocol, on the other hand, starts at 2mg and essentially doubles dose every month for the next 4 months - till it hits 12mg/week. This aggressive titration leads to higher weight loss.

Interestingly, the heart rate increase was see in both RUO reta and Lilly's reta. So, that side effect is compound specific. Sema/tirz did not see any change in heart rates.

Came across this study on RUO reta that was conducted by a Massachusetts based data analytics company nference and published as a preprint (not peer reviewed). I just wanted to share because I found it interesting. I am taking RUO reta so don't flame me! Lol

People who obtained RUO retatrutide outside of trial participation lost an average of 4.7%, 5.3% and 7.2% of their weight after taking it for three months, six months and between six and 12 months, respectively.

By contrast, records on patients who enrolled in Lilly’s trials showed that they lost more than twice as much weight — averages of 5.7%, 11.9% and 15.5%, respectively, at the same time points.

As seen above, the weight lost on RUO reta was more than that shown with semaglutide, about the same as tirzepatide studies, but less that Lilly's reta trials.

Full study here: https://www.preprints.org/frontend/manuscript/4a50510817135f57f7eb38ebedeb03f8/download_pub

Saw this internet based retrospective analysis on Twitter (https://x.com/anthonystaj/status/2078896497127800835), which I thought was interesting to share. The user mined existing online communities on Reddit for people discussing BPC-157 and its adverse events. Analyzed approximately 37,000 comments to date.

• Over 2400 adverse events were reported from 1,370 users.
• Biggest category of adverse events was neuropsych, with anhedonia- the reduced ability to experience pleasure - the most common. Anxiety a close second.
• Headaches and dizziness were most common neurological effects

The analysis includes several caveats/ limitations: there is no estimate on what total number of people that used BPC-157, so hard to get a denominator to determine % of the adverse events.

The point of this analysis was done more so to identify potential adverse events. Interesting analysis ahead of the FDA's meeting later this week. Feel free to share thoughts and discuss

Full results here: https://www.bpc157ae.xyz/